Akero Therapeutics Net Worth
Akero Therapeutics Net Worth Breakdown | AKRO |
Akero Therapeutics Net Worth Analysis
Akero Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Akero Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Akero Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Akero Therapeutics' net worth analysis. One common approach is to calculate Akero Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Akero Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Akero Therapeutics' net worth. This approach calculates the present value of Akero Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Akero Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Akero Therapeutics' net worth. This involves comparing Akero Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Akero Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Akero Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Akero Therapeutics' net worth research are outlined below:
| Akero Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (151.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akero Therapeutics currently holds about 180.72 M in cash with (145.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.81. | |
| Akero Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: LMR Partners LLP Raises Stock Position in Akero Therapeutics, Inc. |
Akero Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Akero Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Akero Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Akero Therapeutics Target Price Consensus
Akero target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Akero Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Akero analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Akero stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Akero Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAkero Therapeutics Target Price Projection
Akero Therapeutics' current and average target prices are 31.20 and 43.56, respectively. The current price of Akero Therapeutics is the price at which Akero Therapeutics is currently trading. On the other hand, Akero Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Akero Therapeutics Market Quote on 22nd of November 2024
Target Price
Analyst Consensus On Akero Therapeutics Target Price
Know Akero Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Akero Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Akero Therapeutics backward and forwards among themselves. Akero Therapeutics' institutional investor refers to the entity that pools money to purchase Akero Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perceptive Advisors Llc | 2024-09-30 | 1.7 M | Boxer Capital Llc | 2024-09-30 | 1.7 M | Geode Capital Management, Llc | 2024-06-30 | 1.6 M | Logos Global Management Lp | 2024-06-30 | 1.6 M | Yiheng Capital Llc | 2024-06-30 | 1.4 M | Redmile Group, Llc | 2024-09-30 | 1.4 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | Baker Bros Advisors Lp | 2024-09-30 | 1.1 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.1 M | Hhg Plc | 2024-06-30 | 6.9 M | Blackrock Inc | 2024-06-30 | 5.6 M |
Follow Akero Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.17 B.Market Cap |
|
Project Akero Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.31) | (0.32) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.28) | (0.27) |
When accessing Akero Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Akero Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Akero Therapeutics' profitability and make more informed investment decisions.
Evaluate Akero Therapeutics' management efficiency
Akero Therapeutics has return on total asset (ROA) of (0.2317) % which means that it has lost $0.2317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.359) %, meaning that it created substantial loss on money invested by shareholders. Akero Therapeutics' management efficiency ratios could be used to measure how well Akero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Akero Therapeutics' Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Net Tangible Assets is likely to grow to about 394.3 M, though Non Currrent Assets Other are likely to grow to (0.95).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.18 | 10.69 | |
| Tangible Book Value Per Share | 10.18 | 10.69 | |
| Enterprise Value Over EBITDA | (6.86) | (7.20) | |
| Price Book Value Ratio | 2.29 | 2.41 | |
| Enterprise Value Multiple | (6.86) | (7.20) | |
| Price Fair Value | 2.29 | 2.41 | |
| Enterprise Value | 1.7 B | 1.8 B |
The strategic initiatives led by Akero Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (0.36) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Akero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Akero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Akero Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Akero Therapeutics Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Akero Therapeutics Earnings Estimation Breakdown
The calculation of Akero Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Akero Therapeutics is estimated to be -0.992575 with the future projection ranging from a low of -1.0675 to a high of -0.959425. Please be aware that this consensus of annual earnings estimates for Akero Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.07 Lowest | Expected EPS | -0.96 Highest |
Akero Therapeutics Earnings Projection Consensus
Suppose the current estimates of Akero Therapeutics' value are higher than the current market price of the Akero Therapeutics stock. In this case, investors may conclude that Akero Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Akero Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 12 | 87.3% | -1.05 | -0.992575 | -3.73 |
Akero Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Akero Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Akero Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Akero Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Akero Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Akero Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Akero Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Akero Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Akero Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.9 | -1.05 | -0.15 | 16 | ||
2024-08-09 | 2024-06-30 | -0.9 | -0.81 | 0.09 | 10 | ||
2024-05-10 | 2024-03-31 | -0.95 | -0.9 | 0.05 | 5 | ||
2024-02-29 | 2023-12-31 | -0.86 | -0.99 | -0.13 | 15 | ||
2023-11-13 | 2023-09-30 | -0.68 | -0.71 | -0.03 | 4 | ||
2023-08-11 | 2023-06-30 | -0.63 | -0.6 | 0.03 | 4 | ||
2023-05-15 | 2023-03-31 | -0.67 | -0.55 | 0.12 | 17 | ||
2023-03-17 | 2022-12-31 | -0.8 | -0.49 | 0.31 | 38 | ||
2022-11-04 | 2022-09-30 | -0.74 | -0.92 | -0.18 | 24 | ||
2022-08-04 | 2022-06-30 | -0.86 | -0.77 | 0.09 | 10 | ||
2022-05-06 | 2022-03-31 | -0.8 | -0.74 | 0.06 | 7 | ||
2022-02-25 | 2021-12-31 | -0.82 | -0.93 | -0.11 | 13 | ||
2021-11-12 | 2021-09-30 | -0.91 | -0.7 | 0.21 | 23 | ||
2021-08-13 | 2021-06-30 | -0.72 | -0.83 | -0.11 | 15 | ||
2021-05-13 | 2021-03-31 | -0.91 | -0.43 | 0.48 | 52 | ||
2021-03-16 | 2020-12-31 | -0.59 | -0.86 | -0.27 | 45 | ||
2020-11-12 | 2020-09-30 | -0.65 | -0.63 | 0.02 | 3 | ||
2020-08-12 | 2020-06-30 | -0.62 | -0.57 | 0.05 | 8 | ||
2020-05-13 | 2020-03-31 | -0.61 | -0.42 | 0.19 | 31 | ||
2020-03-16 | 2019-12-31 | -0.59 | -0.55 | 0.04 | 6 | ||
2019-11-12 | 2019-09-30 | -0.43 | -0.56 | -0.13 | 30 | ||
2019-08-12 | 2019-06-30 | -0.36 | -2.21 | -1.85 | 513 | ||
2019-06-20 | 2019-03-31 | 0 | -0.2263 | -0.2263 | 0 | ||
2019-01-17 | 2018-12-31 | 0 | -0.76 | -0.76 | 0 |
Akero Therapeutics Corporate Management
| Timothy Rolph | CoFounder Officer | Profile | |
| Patrick Lamy | Senior Strategy | Profile | |
| Scott Gangloff | Chief Officer | Profile | |
| Catriona Yale | Executive Officer | Profile | |
| William JD | CFO, VP | Profile | |
| David JD | Vice Legal | Profile |
Already Invested in Akero Therapeutics?
The danger of trading Akero Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akero Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akero Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akero Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.73) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.